# SURPASS ET (NCT04285086)

> Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04285086
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: PharmaEssentia
- Conditions: Essential Thrombocythemia
- Interventions: Ropeginterferon alfa-2b; Anagrelide
- Enrollment: 174
- Primary outcome: Peripheral blood count remission
- Primary outcome: Improvement or non-progression in disease-related signs
- Primary outcome: Large symptoms improvement or maintain non-progression
- Primary outcome: Absence of hemorrhagic or thrombotic events

## Commentary we found

- YouTube: 20
- X threads: 16
- Podcasts: 7
- X videos: 3

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=surpass-et-nct04285086

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04285086", "email": "<work email>"}; the inbox owner confirms by the emailed link.